methyl (S)-(1-hydrazinyl-3,3-dimethyl-1-oxobutan-2-yl)carbamate | 198904-78-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl (S)-(1-hydrazinyl-3,3-dimethyl-1-oxobutan-2-yl)carbamate
• 英文别名: Methyl (1S)-1-(hydrazinocarbonyl)-2,2-dimethylpropylcarbamate；[N-methoxycarbonyl-(L)-tert-leucyl]-hydrazine；(S)-methyl 1-hydrazinyl-3,3-dimethyl-1-oxobutan-2-ylcarbamate；[N-(methoxycarbony)-L-tert-leucinyl]hydrazine；methyl N-[(2S)-1-hydrazinyl-3,3-dimethyl-1-oxobutan-2-yl]carbamate
• CAS: 198904-78-8
• 化学式: C₈H₁₇N₃O₃
• 分子量: 203.241
• InChiKey: UEUCJJITPXHGSU-RXMQYKEDSA-N

物化性质

• 沸点：
  387.3±25.0 °C(Predicted)
• 密度：
  1.111±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  93.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl (S)-(1-hydrazinyl-3,3-dimethyl-1-oxobutan-2-yl)carbamate 在 甲烷磺酸 作用下， 以 异丙醇 、 甲苯 为溶剂， 反应 22.0h， 生成 methyl N-[(2S)-1-[(2E)-2-[[4-(2-tert-butyltetrazol-5-yl)phenyl]methylidene]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
  参考文献：
  名称：

  New Aza-Dipeptide Analogues as Potent and Orally Absorbed HIV-1 Protease Inhibitors:  Candidates for Clinical Development

  摘要：

  On the basis of previously described X-ray studies of an enzyme/aza-dipeptide complex,(8) azadipeptide analogues carrying N-(bis-aryl-methyl) substituents on the (hydroxethyl)hydrazine moiety have been designed and synthesized as HIV-1 protease inhibitors. By using either equally (12) ororthogonally (13) protected dipeptide isosteres, symmetrically and asymmetrically acylated aza-dipeptides can be synthesized. This approach led to the discovery of very potent inhibitors with antiviral activities (ED50) in the subnanomolar range. Acylation of the (hydroxethyl)hydrazine dipeptide isostere with the L-tert-leucine derivative 29 increased the oral bioavailability significantly when compared to the corresponding L-valine or L-isoleucine derivatives. The bis(L-tert-leucine) derivatives CGP 75355, CGP 73547, CGP 75136, and CGP 75176 combine excellent antiviral activity with high blood concentration after oral administration. Furthermore, they show no cross-resistance with saquinavir-resistant strains and maintain activity against indinavir-resistant ones. Consequently they qualify for further profiling as potential clinical candidates.

  DOI：

  10.1021/jm970873c
• 作为产物：
  描述：

  N-甲氧羰基-L-叔亮氨酸 在 N-甲基吗啉 、 盐酸 、 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 1,4-二氧六环 、 乙酸乙酯 为溶剂， 反应 30.0h， 生成 methyl (S)-(1-hydrazinyl-3,3-dimethyl-1-oxobutan-2-yl)carbamate
  参考文献：
  名称：

  [EN] NOVEL AZA-PEPTIDES CONTAINING 2,2-DISUBSTITUTED CYCLOBUTYL AND/OR SUBSTITUTED ALKOXY BENZYL DERIVATIVES AS ANTIVIRALS
  [FR] NOUVEAU AZA-PEPTIDES CONTENANT DU CYCLOBUTYL 2,2-DISUBSTITUÉ ET/OU DES DÉRIVÉS ALCOXY BENZYLE SUBSTITUÉS COMME AGENTS ANTIVIRAUX

  摘要：

  本发明涉及一种包含2,2-二取代的5-环丁基和/或取代烷氧基苄基衍生物的新型氮杂肽，化学式为（I），以及用于抑制人类免疫缺陷病毒（HIV）的组合物和制备这些化合物的方法。

  公开号：

  WO2011080562A1

文献信息

• Synthesis of P1′-Functionalized Macrocyclic Transition-State Mimicking HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol
  作者：Maria De Rosa、Johan Unge、Hitesh V. Motwani、Åsa Rosenquist、Lotta Vrang、Hans Wallberg、Mats Larhed

  DOI：10.1021/jm500434q

  日期：2014.8.14

  Seven novel tertiary alcohol containing linear HIV-1 protease inhibitors (PIs), decorated at the para position of the benzyl group in the P1′ side with (hetero)aromatic moieties, were synthesized and biologically evaluated. To study the inhibition and antiviral activity effect of P1–P3 macrocyclization, 14- and 15-membered macrocyclic PIs were prepared by ring-closing metathesis of the corresponding

  合成了七种新颖的含线性HIV-1蛋白酶抑制剂（PIs）的叔醇，它们在P1'侧的苄基对位装饰有（杂）芳族部分，并对其进行了生物学评估。为了研究P1-P3大环化的抑制作用和抗病毒活性，通过相应线性PI的闭环复分解反应制备了14和15元大环PI。大环化合物比线性前体更具活性，化合物10f（在P1'位置带有2-噻唑基）是该新系列中最有效的PI（K i 2.2 nM，EC 50 0.2μM）。制备并分析了线性和大环PI与HIV-1蛋白酶的共结晶复合物。
• [EN] ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS<br/>[FR] ANALOGUES D'ATAZANAVIR (ATV) POUR TRAITER DES INFECTIONS PAR LE VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2018145021A1

  公开（公告）日：2018-08-09

  The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, the compound of formula (I) for use in therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I. Preferred compounds are N-[(2S) -1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino) -3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(phenyl) methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate atazanavir (ATV) analogues substituted by several heterocycles, such as e.g. pyrazole (Rl); e.g. oxetane (substituent of X2); e.g. pyridine or pyrimidine (X1); e.g. piperazine or 3,8-diazabicyclo[3.2.1]octan (X2).

  该发明提供了一种如下式的化合物：或其药学上可接受的盐。该发明还提供了包含如下式化合物的药物组合物，制备如下式化合物的方法，以及利用如下式化合物治疗HIV病毒增殖、治疗艾滋病或延缓哺乳动物艾滋病症状发作的治疗方法中使用的如下式化合物。首选化合物是N-[(2S)-1-[2-[(2S,3S)-2-羟基-3-[[(2S)-2-(甲氧羰基氨基)-3,3-二甲基丁酰]氨基]-4-苯基丁基]-2-[(苯基)甲基]肼基]-3,3-二甲基-1-氧丁酸-2-基]氨基甲酸酯阿扎那韦（ATV）类似物，其被若干杂环取代，例如吡唑（R1）；例如氧杂环（X2的取代基）；例如吡啶或嘧啶（X1）；例如哌嗪或3,8-二氮杂双环[3.2.1]辛烷（X2）。
• Two-Carbon-Elongated HIV-1 Protease Inhibitors with a Tertiary-Alcohol-Containing Transition-State Mimic
  作者：Xiongyu Wu、Per Öhrngren、Jenny K. Ekegren、Johan Unge、Torsten Unge、Hans Wallberg、Bertil Samuelsson、Anders Hallberg、Mats Larhed

  DOI：10.1021/jm070680h

  日期：2008.2.1

  A new generation of HIV-1 protease inhibitors encompassing a tertiary-alcohol-based transition-state mimic has been developed. By elongation of the core structure of recently reported inhibitors with two carbon atoms and by varying the P1' group of the compounds, efficient inhibitors were obtained with Ki down to 2.3 nM and EC50 down to 0.17 microM. Two inhibitor-enzyme X-ray structures are reported

  已经开发了包含基于叔醇的过渡态模拟物的新一代HIV-1蛋白酶抑制剂。通过延长最近报道的具有两个碳原子的抑制剂的核心结构，并通过改变化合物的P1'基团，可获得有效的抑制剂，其中Ki降至2.3 nM，EC50降至0.17 microM。报道了两种抑制剂-酶的X射线结构。
• [EN] NOVEL AZA-PEPTIDES CONTAINING 2,2-DISUBSTITUTED CYCLOBUTYL AND/OR SUBSTITUTED ALKOXY BENZYL DERIVATIVES AS ANTIVIRALS<br/>[FR] NOUVEAU AZA-PEPTIDES CONTENANT DU CYCLOBUTYL 2,2-DISUBSTITUÉ ET/OU DES DÉRIVÉS ALCOXY BENZYLE SUBSTITUÉS COMME AGENTS ANTIVIRAUX
  申请人：HETERO RESEARCH FOUNDATION

  公开号：WO2011080562A1

  公开（公告）日：2011-07-07

  The present invention relates to novel aza-peptides containing 2,2-disubstituted 5 cyclobutyl and/or substituted alkoxy benzyl derivatives of formula (I) and compositions for inhibiting Human Immunodeficiency Virus (HIV) and process for making the compounds.

  本发明涉及一种包含2,2-二取代的5-环丁基和/或取代烷氧基苄基衍生物的新型氮杂肽，化学式为（I），以及用于抑制人类免疫缺陷病毒（HIV）的组合物和制备这些化合物的方法。
• PROTEASE INHIBITORS HAVING ENHANCED FEATURES
  申请人：Nektar Therapeutics

  公开号：US20170028077A1

  公开（公告）日：2017-02-02

  Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.

  本文提供了具有增强特性的蛋白酶抑制剂化合物，以及用于给药此类化合物的方法。例如，这些化合物可以在不伴随CYP3A4抑制剂的情况下给药，具有增加的治疗指数和/或增加的效力，并且在性质上不易产生抗药性。